Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,454 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,230 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03809000 | A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery(STEEL) | active not recruiting | Phase 2 | 188 | RTOG Foundation, Inc.OTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 |
| clinicaltrials |
| NCT07310433 | Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer | not yet recruiting | Phase 2 | 60 | Yung NAOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC(NeoPSMA) | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07300566 | Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial(FORWARD) | not yet recruiting | Phase 2 | 58 | Joelle HelouOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04655365 | Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.(PROSTEP-002) | active not recruiting | Phase 2 | 50 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299292 | Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | recruiting | Phase 2 | 60 | SMED Clinical ResearchOTHER | 2 | Dec 23, 2025 | clinicaltrials |
| NCT02985957 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)(CheckMate 650) | completed | Phase 2 | 351 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 22, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02452008 | Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03753334 | Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.(RCT-EPAII-BCR) | active not recruiting | Phase 2 | 39 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04037358 | RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers(RAVENS) | completed | Phase 2 | 64 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT00117286 | Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 57 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT07291557 | PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer | not yet recruiting | Phase 2 | 250 | AHS Cancer Control AlbertaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03701581 | 4-aminopyridine Treatment for Nerve Injury | recruiting | Phase 2 / Phase 3 | 70 | John ElfarOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04025372 | INTREPId (INTermediate Risk Erection PreservatIon Trial) | active not recruiting | Phase 2 | 234 | Brigham and Women's HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07282197 | Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 | not yet recruiting | Phase 2 | 40 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03833921 | Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer(APRE) | recruiting | Phase 2 | 130 | Martha MimsOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04176497 | PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study | terminated | Phase 2 | 8 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06353906 | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer(PRIAM) | recruiting | Phase 2 | 27 | The Netherlands Cancer InstituteOTHER | 2 | Dec 8, 2025 | clinicaltrials |
| NCT07268794 | CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer(CONVERT-HB1) | not yet recruiting | Phase 2 | 112 | Fudan UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT01089387 | Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction(INSTIN) | completed | Phase 1 / Phase 2 | 18 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05189457 | First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | active not recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05526989 | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | recruiting | Phase 2 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05893381 | Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)(LUST) | recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07250542 | A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 2 | 30 | baotai LiangOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07251829 | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer | not yet recruiting | Phase 2 | 35 | Srinivas RamanOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | recruiting | Phase 1 / Phase 2 | 39 | Institute of Cancer Research, United KingdomOTHER | 2 | Nov 24, 2025 | clinicaltrials |
| NCT02333435 | Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life(RCT-EPA) | active not recruiting | Phase 2 | 130 | CHU de Quebec-Universite LavalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07164794 | Memantine Hydrochloride in Prostate Cancer Patients | not yet recruiting | Phase 2 | 15 | Bin XuOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07163910 | Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study | recruiting | Phase 2 | 93 | baotai LiangOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04635059 | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer(BLAST) | terminated | Phase 2 | 6 | Medical College of WisconsinOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT06536374 | Folate Study in Men With Advanced Prostate Cancer | not yet recruiting | Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05617040 | Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer | terminated | Phase 1 / Phase 2 | 22 | Barinthus BiotherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03541850 | Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | active not recruiting | Phase 2 | 92 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05100472 | A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer | active not recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03480646 | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 175 | Constellation PharmaceuticalsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02203695 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT05779943 | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | active not recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT06060587 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT03939689 | I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).(ARROW) | completed | Phase 2 | 120 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT05540392 | An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues | active not recruiting | Phase 1 / Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04838626 | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection(GuideView) | completed | Phase 2 / Phase 3 | 195 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT07209878 | 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI | recruiting | Phase 2 / Phase 3 | 100 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05869682 | Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy | recruiting | Phase 2 | 210 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 30, 2025source: clinicaltrials